WebApr 20, 2024 · metastatic gastric or GEJ cancer These types of cancers have a unique set of proteins (called Claudin 18.2). We may be able to use a treatment that targets the … WebDec 16, 2024 · Astellas’ GLOW trial, the second Phase 3 trial in CLDN18.2 positive, HER2-negative locally advanced unresectable or metastatic gastric and GEJ cancers, meets …
Astellas’ Phase III gastric cancer therapy trial meets primary endpoint
WebFeb 1, 2024 · Manish A. Shah, MD, discusses the potential clinical implications of the ongoing phase 3 GLOW trial in Claudin 18.2-positive, HER2-negative … WebMar 21, 2024 · The GLOW and SPOTLIGHT studies are a part of Astellas' gastric cancer development program to investigate targeted treatment options such as zolbetuximab … murdoch international welcome scholarship
Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbe…
WebJan 2, 2024 · Zolbetuximab in combination with a chemotherapy regimen including capecitabine and oxaliplatin (CAPOX) demonstrated positive results in patients with HER2-negative locally advanced unresectable or metastatic gastric and gastroesophageal junction cancers, according to results of GLOW, a phase 3 clinical trial. WebDec 16, 2024 · Astellas’ GLOW trial, the second Phase 3 trial in CLDN18.2 positive, HER2-negative locally advanced unresectable or metastatic gastric and GEJ cancers, meets primary endpoint for progression-free survival (PFS) and key secondary endpoint for overall survival (OS) GLOW results, along with SPOTLIGHT topline results, mark progress in … WebMar 21, 2024 · The GLOW and SPOTLIGHT studies are a part of Astellas' gastric cancer development program to investigate targeted treatment options such as zolbetuximab and address patient needs in locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. In both trials, approximately 38% of these patients had CLDN18.2 … how to open garage door when power goes out